Results 171 to 180 of about 20,467 (242)

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7403-7415, August 2026.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Subclassification of Phenotypic Homozygous Familial Hypercholesterolemia. [PDF]

JACC Asia
Tada H, Harada-Shiba M.
europepmc   +1 more source

Assessment of triglyceride‐glucose composite indices associated mortality risk in diabetes‐related heart failure

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1387-1399, August 2026.
Elevated TyG‐Age significantly increases the risk of heart failure in diabetic patients. Furthermore, combining TyG‐Age with the TRS‐HFDM score greatly enhances predictive capability and mortality risk assessment for these patients. ABSTRACT Background Patients with diabetes are at an increased risk of heart failure.
Qijie Zhao, Xiao Cai, Xing Wang, Jing Jin   +3 more
wiley   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, Volume 300, Issue 2, Page 131-152, August 2026.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

The functional landscape of coding variation in the familial hypercholesterolemia gene <i>LDLR</i>. [PDF]

Science
Tabet DR, Coté AG, Lancaster MC, Weile J, Rayhan A, Fotiadou I, Kishore N, Li R, Kuang D, Knapp JJ, Carrero CS, Taverniti O, Axakova A, Castelli JMP, Islam MM, Sowlati-Hashjin S, Gandhi A, Maaieh R, Garton M, Matreyek K, Fowler DM, Bourbon M, Pfisterer SG, Glazer AM, Kroncke BM, Parikh VN, Ashley EA, Knowles JW, Claussnitzer M, Cirulli ET, Hegele RA, Roden DM, MacRae CA, Roth FP.   +33 more
europepmc   +1 more source

Metformin Partially Attenuates Simvastatin‐Induced Myotoxic Responses in C2C12 Myotubes Through Metabolic Adaptation

The FASEB Journal, Volume 40, Issue 13, 15 July 2026.
Simvastatin induces metabolic suppression, mitochondrial dysfunction, and atrophy‐related responses in skeletal muscle cells. In differentiated C2C12 myotubes, metformin partially attenuates these alterations by preserving myotube structural integrity, reducing cellular stress signaling, and maintaining mitochondrial network organization despite ...
Chuqi He, Mike Wesselink, Jelle Y. Huijts, Zhenjia Zhong, Moritz Eggelbusch, Richard T. Jaspers, Rob C. I. Wüst   +6 more
wiley   +1 more source

Case Report: Compound heterozygous familial hypercholesterolemia in a pediatric patient with multiple cutaneous xanthomas. [PDF]

Front Pediatr
Yang Q, Jiang L, Wei X, Lv X, Zhao Y, Liu G.   +5 more
europepmc   +1 more source

Novel Therapies, Residual Risk, Familial Hypercholesterolemia, and Digital Tools: Multispecialty Insights from a Dyslipidemia Management Survey. [PDF]

J Clin Med
Mesquita-Lousada A, Rocha-Melo-Sousa A, Teixeira C, Guimarães TR, Marques-Vieira M, Andrade JP, Ribeiro H, Neiva-Sousa M, Rocha-Neves J.   +8 more
europepmc   +1 more source

Clinical Impact of Familial Hypercholesterolemia on Lower Extremity Artery Disease in Premature Patients. [PDF]

Ann Vasc Dis
Ito E, Ohki T, Yoshida H, Kaneko K.
europepmc   +1 more source